Page last updated: 2024-11-07

1-o-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-O-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid: a mefenamic acid metabolite from urine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128135
CHEMBL ID3527501
MeSH IDM0223810

Synonyms (21)

Synonym
mefenamic acid glucuronide
(2s,3s,4s,5r,6s)-6-[2-(2,3-dimethylanilino)benzoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
beta-d-glucopyranuronic acid, 1-(2-((2,3-dimethylphenyl)amino)benzoate)
mefenamic acid 1-o-acylglucuronide
1-o-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid
102623-18-7
unii-ox5h10g1rg
ox5h10g1rg ,
mefenamic acyl-beta-d-glucuronide
.beta.-d-glucopyranuronic acid, 1-(2-((2,3-dimethylphenyl)amino)benzoate)
mefenamic acyl-.beta.-d-glucuronide
CHEMBL3527501
J-000742
mefenamic acyl-?-d-glucuronide
mefenamic acyl-beta-d glucuronide
beta-d-glucopyranuronic acid, 1-[2-[(2,3-dimethylphenyl)amino]benzoate]
Q27285900
1-o-[2-(2,3-dimethylanilino)benzoyl]hexopyranuronic acid
DTXSID90907958
1-[2-[(2,3-dimethylphenyl)amino]benzoate] beta-d-glucopyranuronic acid
mefenamic acyl- beta -d-glucuronide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1222970Half life in rat hepatocytes at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222965Drug level in cryopreserved human hepatocytes treated with 100 uM MFA at 60 mins incubation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222972Drug level in rat hepatocytes treated with at 100 uM MFA by LC-MS/MS analysis in presence of 1000 uM (-)-borneol (Rvb = 619 +/-158)2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222960Drug level in rat hepatocytes treated with 100 uM MFA after 60 mins2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222984Half life in potassium phosphate buffer at 1 uM at pH 7.4 at 37 degC2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222967Drug level in rat hepatocytes treated with 500 uM MFA by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222964Drug level in cryopreserved human hepatocytes treated with 100 uM MFA at 10 mins incubation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222953Retention time in rat hepatocytes treated with 100 uM MFA by positive ion LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222969Drug level in rat hepatocytes treated with 62.5 uM MFA by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222986Drug level in Sprague-Dawley rat bile treated with 100 mg/kg, ip MFA after 6 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222973Drug level in rat hepatocytes treated with at 100 uM MFA by LC-MS/MS analysis in presence of 1000 uM Lauric acid (Rvb = 619 +/-158)2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.92 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]